Emerging Treatment Option for Hypercholesterolemia

Azelia Brown, Mercer University College of Pharmacy

Elevated blood levels of low density lipoproteins (LDL) are stated to increase risk for atherosclerotic cardiovascular events.  Statins are the reported agent of choice with proven efficacy, though variation in therapeutic response may require the use of additional therapy. [1]

Serine protease proprotein convertase subtilisin–kexin type 9 (PCSK9) is an enzyme that promotes the degradation of LDL receptors which reduces LDL re-uptake and leads to increased LDL levels. [2]  Some PCSK9 agents are monoclonal antibodies that work by sequestering PCSK9 and preventing it from binding to LDL receptors. Inclisiran interferes with ribonucleic acid, reducing the hepatic production PCSK9. [3]

Continue reading


Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events

Elizabeth Lai, Mercer University College of Pharmacy

The National Cholesterol Education Program’s 2004 Updated Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) guidelines and 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines have been used to determine statin eligibility over the last decade.  According to a review article, the 2013 ACC/AHA cholesterol guidelines group management of cholesterol by benefit from statin therapy.  It also includes improved risk assessment for the rest of the population by use of a global cardiovascular disease (CVD) risk calculator.1

A review of the 2013 ACC/AHA cholesterol guidelines suggests a new standard for treating cholesterol and focuses on using the appropriate intensity of statin therapy compared to the previous ATP III guideline which recommended treatment based on specific low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (HDL-C) treatment goals.2

Continue reading